VEGFA and nonpapillary renal cell carcinoma: Since various targeted agents were developed into the treatment strategies of ccRCC patients, such as inhibitors of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), the prognostic outcomes of patients have been greatly improved 7.